Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue.

ABSTRACT:

Background

Fatigue is the most common symptom of MS and has no effective pharmacotherapy.

Objective

To determine the tolerability, safety, and efficacy of low-dose ketamine infusion for MS-related fatigue.

Methods

In this double-blind, randomized, active-placebo-controlled trial, 18 subjects with multiple sclerosis (MS) and reported fatigue received a single intravenous infusion of ketamine (0.5 mg/kg) or midazolam (0.05 mg/kg). The primary outcome was change in Daily Fatigue Severity (DFS) for 7 days following the infusion. Secondary outcomes included Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS) measured up to day 28 post-infusion. We analyzed changes in all outcomes using mixed-effect models.

Results

In total, 18 participants were enr

SUBMITTER: Fitzgerald KC 

PROVIDER: S-EPMC7790846 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature